Kester Capital

Chiltern

Sector
Healthcare
Status
Realised
Date of investment
2010
Key contacts
Adam Maidment
Visit website
www.chiltern.com

Chiltern

Chiltern is a leading, global contract research organisation (“CRO”). The business offers a broad range of clinical CRO services for the pharmaceutical, biotech and medical device industries across a wide spectrum of therapeutic areas. The business serves its international client base from its office network across 35 countries. The CRO market has strong medium-term growth characteristics driven by: a continued increase in R&D spend by the biopharma industry; the growing worldwide regulatory burden associated with new drug applications; and, the continued trend to outsource CRO activities.

Kester Capital sold Chiltern in December 2013, generating a 2.2x return for Kester Capital funds.